Matches in SemOpenAlex for { <https://semopenalex.org/work/W2995434566> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- W2995434566 endingPage "S448" @default.
- W2995434566 startingPage "S448" @default.
- W2995434566 abstract "The anti-PD1 nivolumab, as monotherapy, is indicated for adjuvant treatment of adults with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection. We conducted a cost-utility analysis with the objective of evaluating nivolumab efficiency in France. A 3-state partitioned survival model, comprising recurrence-free survival (RFS), post-recurrence survival and death simulated a cohort of French patients within the adjuvant indication over 20 years. Standard recommended comparators, matching the population of indication, were observation and low dose interferon (LD-IFN). The model used clinical data from pivotal phase III trial Checkmate 238 comparing nivolumab to ipilimumab. Ipilimumab, not approved for adjuvant treatment of melanoma in Europe, was used as connecting strategy within the network meta-analysis used to estimate relative efficacy of nivolumab versus comparators. RFS and overall survival (OS) were extrapolated with parametric distributions using as reference the placebo arm from study CA184-029. As OS data is not available in CheckMate 238 to date, a predictive model based on RFS-OS correlation equation was used; as scenario, nivolumab OS was conservatively assumed equivalent to ipilimumab OS in CA184-029. Utilities were derived from EQ-5D data collected in Checkmate 238. Costs consisted of acquisition and administration, monitoring, subsequent therapies, palliative care, adverse events and transportation. Costs for active treatments were based on drug public prices. In both base case and conservative scenarios, nivolumab respectively resulted in a discounted total of 9.62 and 8.47 life-years and 7.76 and 6.97 quality-adjusted life years (QALY). The efficiency frontier consisted of observation, LD-IFN and nivolumab. The incremental cost-utility ratio (ICUR) of nivolumab was respectively 34,620 €/QALY and 68,928 €/QALY versus LD-IFN (incremental costs: 44,992 € and 35,667 €, incremental QALY: 1.30 and 0.52). Using two different scenarios, this analysis suggested that nivolumab was a cost-effective strategy as adjuvant treatment of adults with melanoma in France." @default.
- W2995434566 created "2019-12-26" @default.
- W2995434566 creator A5001569554 @default.
- W2995434566 creator A5035574764 @default.
- W2995434566 creator A5041899964 @default.
- W2995434566 creator A5045519884 @default.
- W2995434566 creator A5057424560 @default.
- W2995434566 creator A5080247056 @default.
- W2995434566 creator A5080756848 @default.
- W2995434566 creator A5091439412 @default.
- W2995434566 date "2019-11-01" @default.
- W2995434566 modified "2023-10-16" @default.
- W2995434566 title "PCN66 A COST-UTILITY ANALYSIS OF NIVOLUMAB IN THE ADJUVANT TREATMENT OF MELANOMA IN FRANCE" @default.
- W2995434566 doi "https://doi.org/10.1016/j.jval.2019.09.263" @default.
- W2995434566 hasPublicationYear "2019" @default.
- W2995434566 type Work @default.
- W2995434566 sameAs 2995434566 @default.
- W2995434566 citedByCount "0" @default.
- W2995434566 crossrefType "journal-article" @default.
- W2995434566 hasAuthorship W2995434566A5001569554 @default.
- W2995434566 hasAuthorship W2995434566A5035574764 @default.
- W2995434566 hasAuthorship W2995434566A5041899964 @default.
- W2995434566 hasAuthorship W2995434566A5045519884 @default.
- W2995434566 hasAuthorship W2995434566A5057424560 @default.
- W2995434566 hasAuthorship W2995434566A5080247056 @default.
- W2995434566 hasAuthorship W2995434566A5080756848 @default.
- W2995434566 hasAuthorship W2995434566A5091439412 @default.
- W2995434566 hasBestOaLocation W29954345661 @default.
- W2995434566 hasConcept C121608353 @default.
- W2995434566 hasConcept C126322002 @default.
- W2995434566 hasConcept C143998085 @default.
- W2995434566 hasConcept C197934379 @default.
- W2995434566 hasConcept C2777701055 @default.
- W2995434566 hasConcept C2777863537 @default.
- W2995434566 hasConcept C2780030458 @default.
- W2995434566 hasConcept C2781433595 @default.
- W2995434566 hasConcept C2908647359 @default.
- W2995434566 hasConcept C71924100 @default.
- W2995434566 hasConcept C72563966 @default.
- W2995434566 hasConcept C99454951 @default.
- W2995434566 hasConceptScore W2995434566C121608353 @default.
- W2995434566 hasConceptScore W2995434566C126322002 @default.
- W2995434566 hasConceptScore W2995434566C143998085 @default.
- W2995434566 hasConceptScore W2995434566C197934379 @default.
- W2995434566 hasConceptScore W2995434566C2777701055 @default.
- W2995434566 hasConceptScore W2995434566C2777863537 @default.
- W2995434566 hasConceptScore W2995434566C2780030458 @default.
- W2995434566 hasConceptScore W2995434566C2781433595 @default.
- W2995434566 hasConceptScore W2995434566C2908647359 @default.
- W2995434566 hasConceptScore W2995434566C71924100 @default.
- W2995434566 hasConceptScore W2995434566C72563966 @default.
- W2995434566 hasConceptScore W2995434566C99454951 @default.
- W2995434566 hasLocation W29954345661 @default.
- W2995434566 hasOpenAccess W2995434566 @default.
- W2995434566 hasPrimaryLocation W29954345661 @default.
- W2995434566 hasRelatedWork W2780485172 @default.
- W2995434566 hasRelatedWork W2899127460 @default.
- W2995434566 hasRelatedWork W2947988614 @default.
- W2995434566 hasRelatedWork W2983304924 @default.
- W2995434566 hasRelatedWork W3005150264 @default.
- W2995434566 hasRelatedWork W3174164643 @default.
- W2995434566 hasRelatedWork W3175085288 @default.
- W2995434566 hasRelatedWork W4206770832 @default.
- W2995434566 hasRelatedWork W4295836810 @default.
- W2995434566 hasRelatedWork W4319660705 @default.
- W2995434566 hasVolume "22" @default.
- W2995434566 isParatext "false" @default.
- W2995434566 isRetracted "false" @default.
- W2995434566 magId "2995434566" @default.
- W2995434566 workType "article" @default.